Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen GAAP Cost of Sales as % of Product Sales by Year
GAAP Cost of Sales as % of Product Sales (%) (%)
Amgen GAAP Cost of Sales as % of Product Sales: 34.2% in FY2025, down 5.9 pts from a year earlier.
Latest, FY2025
34.2%
Period ended Dec 31, 2025
Change on a year earlier
-5.9 pts
40.1% in FY2024
History
9 years
Since FY2017
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| GAAP cost of sales as a percentage of product sales | 31.8 | % | 35.7 | % | 34.2 | % | 40.1 | %”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Reconciliations of GAAP to Non-GAAP Measures.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | GAAP Cost of Sales as % of Product Sales (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.2% | -5.9 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 40.1% | +8.7 pts | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 31.4% | +5.6 pts | Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗ |
| FY2022 | Dec 31, 2022 | 25.8% | -0.8 pts | Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 26.6% | +1.2 pts | Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗ |
| FY2020 | Dec 31, 2020 | 25.4% | +5.8 pts | Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗ |
| FY2019 | Dec 31, 2019 | 19.6% | +1.4 pts | Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗ |
| FY2018 | Dec 31, 2018 | 18.2% | -0.5 pts | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
| FY2017 | Dec 31, 2017 | 18.7% | – | Form 8-K (amgn-20181231xq4exhibit991.htm, filed 2019-01-29) ↗ |
Cite this data
StockData. (2026). Amgen GAAP Cost of Sales as % of Product Sales (%), annual FY2017–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/gaap-cogs-pct
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.